Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL

(1:49)

Glofitamab in R/R DLBCL: updated safety and efficacy data

(5:30)

Glofitamab and obinutuzumab in r/r MCL

(5:44)

Glofitamab and polatuzumab vedotin in DLBCL

(5:46)

Preliminary results from NP40126: Glofitamab and R-CHOP in NHL

(1:43)

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

(2:54)

Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis

(2:18)

CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamab

(1:21)

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

(3:2)

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

(3:26)

Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL

(2:2)

Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023

(4:22)

COALITION: glofitamab-R-CHOP or glofitamab-pola-R-CHP in younger patients with high-risk LBCL

(7:14)

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

(4:46)

Glofitamab plus R-ICE chemotherapy in R/R DLBCL: a Phase Ib study

(3:31)

The emerging potential of bispecific antibodies as monotherapy \u0026 in combination for B-cell lymphoma

(5:12)

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

(3:26)

Glofitamab \u0026 Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma -Blood Cancers Video Library

(3:52)

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

(2:21)